Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps2-10-96 | Nodules & Cancer | ETA2022

Prospective, observational study on radioiodine treatment in DTC patients with intermediate RISK or micro lymph node metastases

Blewaska Aleksandra , Ledwon Aleksandra , Paliczka-Cieslik Ewa , Sygula Aleksandra , Haras-Gil Malgorzata , Kropinska Aleksandra , Czarniecka Agnieszka , Handkiewicz-Junak Daria

There are much controversy adjuvant radioiodine treatment (131-I-th) in intermediate or low risk patients with lymph node micrometastases. The first results of ESTIMABL2 trial showed no radioiodine benefit in low risk DTC, however intermediate patients were not included in this study.Aim: Observational study was to evaluate effects of 131-I-th in intermediate/low risk DTC patients.Patients: There were 342 women (85%), the median ag...

ea0092ps3-27-05 | Thyroid Cancer clinical 3 | ETA2023

Changes in clinical presentation of paediatric differentiated thyroid cancer (DTC) treated in one centre over 40 years

Kropinska Aleksandra , Ledwon Aleksandra , Paliczka Cieslik Ewa , Olczyk Tomasz , Blewąska Aleksandra , Krzempek Marcela , Wilk Agata , Cortez Alexander , Czarniecka Agnieszka , Jarzab Barbara , Handkiewicz Junak Daria

Background: Differentiated thyroid carcinoma (DTC) in children is a rare cancer, occurring in 1/100,000 children/year. In the adults a steady increase in the incidence and change in presentation of DTC has been observed over the past 30 years.Purpose: Evaluation of changes in the clinical presentation of paediatric DTC on the example of children treated in Institute of Oncology in Gliwice between 1970 and 2015.Material and methods:...

ea0092ps1-01-09 | Cancer | ETA2023

Risk of renal adverse effects in patients with advanced thyroid cancer who are undergoing radiological monitoring, with a particular focus on patients receiving tyrosine kinase inhibitors

Haras-Gil Malgorzata , Samborski Konrad , Ledwon Aleksandra , Kolton Magdalena , Handkiewicz-Junak Daria , Jarzab Barbara , Krajewska Jolanta

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...

ea0049ep1440 | Thyroid (non-cancer) | ECE2017

Management of treatment-related toxicity caused by multi kinase inhibitors administered due to advanced thyroid carcinoma

Krajewska Jolanta , Kukulska Aleksandra , Handkiewicz-Junak Daria , Paliczka-Cieslik Ewa , Olczyk Tomasz , Gawlik Tomasz , Ledwon Aleksandra , Michalik Barbara , Jarzab Barbara

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

ea0070aep923 | Thyroid | ECE2020

Adverse effects of tyrosine kinase inhibitors in advanced thyroid carcinoma – a summary of 10-year experience

Krajewska Jolanta , Kukulska Aleksandra , Paliczka-Cieslik Ewa , Gawlik Tomasz , Olczyk Tomasz , Ledwon Aleksandra , Michalik Barbara , Kropinska Aleksadra , Handkiewicz-Junak Daria , Jarzab Barbara

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...